

## Author's Accepted Manuscript

Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir

Miguel M. Leiva-Juarez, Carson T. Kirkpatrick, Brian E. Gilbert, Brenton Scott, Michael J. Tuvim, Burton F. Dickey, Scott E. Evans, Diane Markesich



PII: S0014-2999(17)30684-2  
DOI: <https://doi.org/10.1016/j.ejphar.2017.10.035>  
Reference: EJP71473

To appear in: *European Journal of Pharmacology*

Received date: 24 July 2017  
Revised date: 18 October 2017  
Accepted date: 19 October 2017

Cite this article as: Miguel M. Leiva-Juarez, Carson T. Kirkpatrick, Brian E. Gilbert, Brenton Scott, Michael J. Tuvim, Burton F. Dickey, Scott E. Evans and Diane Markesich, Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2017.10.035>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir**

Miguel M. Leiva-Juarez<sup>1</sup>, Carson T. Kirkpatrick<sup>1</sup>, Brian E. Gilbert<sup>2</sup>, Brenton Scott<sup>3</sup>, Michael J. Tuvim<sup>1</sup>, Burton F. Dickey<sup>1,4</sup>, Scott E. Evans<sup>1,41\*</sup>, Diane Markesich<sup>31</sup>

<sup>1</sup>Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

<sup>2</sup>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

<sup>3</sup>Pulmotect, Inc., Houston, Texas, USA

<sup>4</sup>The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA

\*Corresponding author: Scott E. Evans, MD, Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1100, Houston, Texas 77030. (713) 563-7433. [seevans@mdanderson.org](mailto:seevans@mdanderson.org)

**ABSTRACT**

Influenza pneumonia remains a common and debilitating viral infection despite vaccination programs and antiviral agents developed for prophylaxis and treatment. The neuraminidase inhibitor oseltamivir is frequently prescribed for established influenza A virus infections, but the emergence of neuraminidase inhibitor resistant viruses, a brief therapeutic window and competing diagnoses complicate its use. PUL-042 is a clinical

---

<sup>1</sup> These authors contributed equally to this manuscript

Download English Version:

<https://daneshyari.com/en/article/8529862>

Download Persian Version:

<https://daneshyari.com/article/8529862>

[Daneshyari.com](https://daneshyari.com)